Table 3.

Absorbance measurements of autoantibodies and their association with breast cancer

AutoantibodyNormal mammogram (n = 200)Breast cancer (n = 200)P valueaORb95% CIIncrease in c-statisticcP value
CD3200.15 (0.12)0.16 (0.12)0.621.100.90–1.350.0000.96
EPHA20.13 (0.06)0.16 (0.10)0.00061.641.21–2.240.0340.037
GFRA10.18 (0.06)0.20 (0.08)0.00811.281.03–1.590.0130.32
IGFBP20.21 (0.12)0.25 (0.13)0.00061.391.10–1.750.0300.050
CST20.17 (0.09)0.20 (0.10)0.00131.391.12–1.730.0260.13
GAL10.17 (0.06)0.20 (0.07)<0.00011.751.37–2.230.0510.021
HER-20.13 (0.04)0.15 (0.06)<0.00011.651.28–2.130.0390.054
LAMC20.15 (0.05)0.17 (0.08)0.00071.471.16–1.880.0250.13
ANGPTL40.18 (0.05)0.20 (0.06)0.00011.571.24–1.990.0410.032
DKK10.18 (0.10)0.24 (0.11)<0.00011.771.40–2.240.0600.0093
MUC10.14 (0.06)0.18 (0.08)<0.00011.831.41–2.370.0550.012
SSR20.14 (0.07)0.17 (0.08)0.00071.531.23–1.920.0290.14
LRP100.14 (0.05)0.15 (0.07)0.00981.351.09–1.680.0110.47
LRRC150.11 (0.04)0.12 (0.05)0.301.090.89–1.340.0010.82
SPINT20.15 (0.07)0.18 (0.09)0.00221.401.13–1.740.0180.31
SPON20.14 (0.07)0.17 (0.08)<0.00011.651.31–2.070.0420.052
CD1470.10 (0.05)0.12 (0.06)0.00391.431.15–1.780.0160.38
CDH30.10 (0.04)0.12 (0.04)0.00331.431.14–1.790.0140.40
GRN0.12 (0.06)0.13 (0.07)0.191.160.94–1.430.0040.65
SUSD20.12 (0.04)0.13 (0.05)0.00851.361.10–1.700.0130.38

NOTE: Data shown as mean (SD) of Embedded Image.

  • aDifferences between groups were tested using t tests. Significant Bonferroni adjusted P value < 0.05/20 = 0.0025 are shown in bold.

  • bOR (95% CI) for breast cancer prevalence per 1 SD increase in autoantibody was determined using logistic regression models adjusted for age, race, BMI, and current smoking status.

  • cChange in area under the ROC curve (i.e., c-statistic) was determined when autoantibody was added to the adjusted logistic regression models.